Itching for answers: new study probes immunotherapy side effects
NCT ID NCT05689463
First seen Feb 06, 2026 · Last updated May 16, 2026 · Updated 13 times
Summary
This study aims to find out how often patients on immunotherapy (cancer treatments like pembrolizumab or nivolumab) who have chronic itching also have certain antibodies (BP180 and BP230) in their blood. Researchers will enroll 100 adults with itching that started after immunotherapy and lasted more than a month. The goal is to better understand the cause of this itching and whether it might lead to skin conditions like blisters or rashes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH CHRONIC PRURITUS FOR MORE THAN 1 MONTH WHO HAVE RECEIVED IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UHRouen
RECRUITINGRouen, France
Contact
Conditions
Explore the condition pages connected to this study.